Open AccessOral fosfomycin for the treatment of chronic bacterial prostatitis
Author(s) -
Ilias Karaiskos,
Lambrini Galani,
Vissaria Sakka,
Aikaterini Gkoufa,
Odysseas Sopilidis,
Dimitrios Chalikopoulos,
Gerasimos Alivizatos,
E. Giamarellou
Publication year - 2019
Publication title -
the journal of antimicrobial chemotherapy/journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkz015
Subject(s) - fosfomycin , medicine , prostatitis , chronic bacterial prostatitis , antibiotics , enterococcus faecalis , adverse effect , regimen , gastroenterology , microbiology and biotechnology , prostate , biology , staphylococcus aureus , bacteria , genetics , cancer
Chronic bacterial prostatitis (CBP) is a difficult-to-treat infection as only a few antibiotics achieve therapeutic concentrations in the prostate. Data on the efficacy and safety of oral fosfomycin for the treatment of CBP are limited.